IMI’s advisory and “hands-on” strategic support have resulted in the following for its Clients:
Marketing Strategies/Implementation
- Conducted numerous “repositionings” of technologies resulting in value-creation for deal-making and investments (6-7 cancer, epilepsy, drug delivery, etc. technologies)
- HC Division becoming the no. 1 profit provider in its conglomerate
- Achievement of market leadership in Europe and the U.S.A. for a CNS product
- European strategy and sales call target development for a major drug delivery company resulting in significant sales increase
IMI’s transaction-oriented consulting has resulted in the following for its Clients:
Business Development & Licensing, M&A, Capital Raising
- Completed or influenced 25 transactions for Clients in Biotech, Pharma and Diagnostics having negotiated ca. 45 transactions
- Concluded a reputable biotech R&D collaboration, assuring the Client’s closure of successful financing rounds
- Completed a 7-country European alliance having a value of 1.1 Billion Euro (not discounted)
- Raised capital for creation of a U.S.A. Biotech Fund, helped set-up Fund
- Raised capital for 2 Biotech companies
|
